Bipolar Disorder - US Drug Forecast and Market Analysis to 2024
|出版日期||內容資訊||英文 312 Pages
|躁鬱症:美國的醫藥品市場預測與分析 Bipolar Disorder - US Drug Forecast and Market Analysis to 2024|
|出版日期: 2016年03月01日||內容資訊: 英文 312 Pages||
本報告提供美國的躁鬱症治療藥臨床實驗趨勢與上市預測相關分析，躁鬱症概要和症狀、原因，目前的主要的治療方法，現在臨床實驗中的開發中產品的概要 (功效，SWOT分析等)，市場規模預測 (今後11年份)，主要的推動市場要素與其影響度等相關調查評估。
Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka's Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.
GlobalData estimates that drug sales for bipolar disorder in the US reached $4.5 billion during 2014, making the US the largest market within the 8MM. A steep decline in sales is forecast to occur between 2015 and 2017, attributed largely to the generic erosion of Otsuka's Abilify. This will be followed by a more gradual contraction in market size between 2017 and 2020 due to the generic erosion of other key brands such as Dainippon Sumitomo's Latuda and AstraZeneca's Seroquel XR.